Anti-cancer and potential chemopreventive actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-inflammatory pathways

Gillis CN: Panax ginseng pharmacology: a nitric oxide link?. Biochem Pharmacol. 1997, 54 (1): 1-8. 10.1016/S0006-2952(97)00193-7. Yue PY, Mak NK, Cheng YK, Leung KW, Ng TB, Fan DT, Yeung HW, Wong RN: Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chin Med. 2007, 2: 6-10.1186/1749-8546-2-6. Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev. 2004, 9 (3): 259-274. Saita T, Katano M, Matsunaga H, Kouno I, Fujito H, Mori M: Screening of polyacetylenic alcohols in crude drugs using the ELISA for panaxytriol. Biol Pharm Bull. 1995, 18 (7): 933-937. Matsunaga H, Saita T, Nagumo F, Mori M, Katano M: A possible mechanism for the cytotoxicity of a polyacetylenic alcohol, panaxytriol: inhibition of mitochondrial respiration. Cancer Chemother Pharmacol. 1995, 35 (4): 291-296. 10.1007/BF00689447. Yun TK: Panax ginseng--a non-organ-specific cancer preventive?. Lancet Oncol. 2001, 2 (1): 49-55. 10.1016/S1470-2045(00)00196-0. Li W, Kong AN: Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog. 2009, 48 (2): 91-104. 10.1002/mc.20465. Gum SI, Jo SJ, Ahn SH, Kim SG, Kim JT, Shin HM, Cho MK: The potent protective effect of wild ginseng (Panax ginseng C.A. Meyer) against benzo[alpha]pyrene-induced toxicity through metabolic regulation of CYP1A1 and GSTs. J Ethnopharmacol. 2007, 112 (3): 568-576. 10.1016/j.jep.2007.05.014. Ng F, Yun H, Lei X, Danishefsky SJ, Fahey J, Stephenson K, Flexner C, Lee L: (3R, 9R, 10R)-Panaxytriol: A molecular-based nutraceutical with possible application to cancer prevention and treatment. Tetrahedron Lett. 2008, 49 (50): 7178-7179. 10.1016/j.tetlet.2008.09.169. Hwang YP, Jeong HG: Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells. Toxicol Appl Pharmacol. 2010, 242 (1): 18-28. 10.1016/j.taap.2009.09.009. Morris CA, Avorn J: Internet marketing of herbal products. Jama. 2003, 290 (11): 1505-1509. 10.1001/jama.290.11.1505. DeAngelis CD, Fontanarosa PB: Drugs alias dietary supplements. Jama. 2003, 290 (11): 1519-1520. 10.1001/jama.290.11.1519. Dietz BM, Liu D, Hagos GK, Yao P, Schinkovitz A, Pro SM, Deng S, Farnsworth NR, Pauli GF, van Breemen RB, Bolton JL: Angelica sinensis and its alkylphthalides induce the detoxification enzyme NAD(P)H: quinone oxidoreductase 1 by alkylating Keap1. Chem Res Toxicol. 2008, 21 (10): 1939-1948. 10.1021/tx8001274. Yun TK: Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. Mutat Res. 2003, 523-524: 63-74. Shibata S: Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci. 2001, 16 (Suppl): S28-37. Chang YS, Seo EK, Gyllenhaal C, Block KI: Panax ginseng: a role in cancer therapy?. Integr Cancer Ther. 2003, 2 (1): 13-33. 10.1177/1534735403251167. Jia L, Zhao Y, Liang XJ: Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem. 2009, 16 (22): 2924-2942. 10.2174/092986709788803204. Xiang YZ, Shang HC, Gao XM, Zhang BL: A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res. 2008, 22 (7): 851-858. 10.1002/ptr.2384. Qi LW, Wang CZ, Yuan CS: American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol. 2010, 80 (7): 947-954. 10.1016/j.bcp.2010.06.023. Ni W, Zhang X, Wang B, Chen Y, Han H, Fan Y, Zhou Y, Tai G: Antitumor activities and immunomodulatory effects of ginseng neutral polysaccharides in combination with 5-fluorouracil. J Med Food. 2010, 13 (2): 270-277. 10.1089/jmf.2009.1119. Cheng H, Li S, Fan Y, Gao X, Hao M, Wang J, Zhang X, Tai G, Zhou Y: Comparative studies of the antiproliferative effects of ginseng polysaccharides on HT-29 human colon cancer cells. Med Oncol. 2010, Zeng Y: Adjunctive therapy of Ginseng Polysaccharide for lung cancer. China Pharmaceuticals. 2001, 10 (6): 31-32. Fu W, Chen L, Huang S, Zou H: The role of Panax ginseng polysaccharide injection in chemotherapy of patients with ovarian cancer. Pharm Care & Res. 2005, 5 (2): 169-171. Xie F, Zeng Z, Huang H, Zhao C, Lu T: Clinical observation on nasopharyngeal carcinoma treated with combined therapy of radiotherapy and ginseng polysaccharide injection. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001, 21 (5): 332-334. Liu J, Sun L, Zhao Y, Zhou T, Zhang J, Sui G, Wu J, Zhou J, Fu L, Lu Q, Liu G, Hui M: Clinical phase II study on immunoimprovement of patients with breast cancer treated by Shenyi capsule. Chin J Clin Oncol. 2000, 27 (7): 534-536. Liu S, Sun L, Ban L, Zhou T: Ginsenoside Rg3 capsules combined NP regimen in the treatment of advanced non-small cell lung cancer. Chin Clin Oncol. 2007, 12 (11): 847-849. Wang H, Li X: The application of shengmai injection in malignant tumor. Mod Chin Med. 2003, 16-17. 3 Berenblum I, Armuth V: Two independent aspects of tumor promotion. Biochim Biophys Acta. 1981, 651 (1): 51-63. Heidelberger C, Freeman AE, Pienta RJ, Sivak A, Bertram JS, Casto BC, Dunkel VC, Francis MW, Kakunaga T, Little JB, Schechtman LM: Cell transformation by chemical agents--a review and analysis of the literature. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res. 1983, 114 (3): 283-385. Weinberg F, Chandel NS: Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci. 2009, 66 (23): 3663-3673. 10.1007/s00018-009-0099-y. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454 (7203): 436-444. 10.1038/nature07205. Aggarwal BB, Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006, 71 (10): 1397-1421. 10.1016/j.bcp.2006.02.009. Juge N, Mithen RF, Traka M: Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. 2007, 64 (9): 1105-1127. 10.1007/s00018-007-6484-5. Wattenberg LW: Chemoprevention of cancer. Cancer Res. 1985, 45 (1): 1-8. Hsu CH, Cheng AL: Clinical studies with curcumin. Adv Exp Med Biol. 2007, 595: 471-480. full_text. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV: Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008, 65 (11): 1631-1652. 10.1007/s00018-008-7452-4. Xu C, Li CY, Kong AN: Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005, 28 (3): 249-268. 10.1007/BF02977789. Valgimigli L, Iori R: Antioxidant and pro-oxidant capacities of ITCs. Environ Mol Mutagen. 2009, 50 (3): 222-237. 10.1002/em.20468. Yu S, Kong AN: Targeting carcinogen metabolism by dietary cancer preventive compounds. Curr Cancer Drug Targets. 2007, 7 (5): 416-424. 10.2174/156800907781386669. Shen G, Kong AN: Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm Drug Dispos. 2009, 30 (7): 345-355. 10.1002/bdd.680. Yuan JH, Li YQ, Yang XY: Inhibition of epigallocatechin gallate on orthotopic colon cancer by upregulating the Nrf2-UGT1A signal pathway in nude mice. Pharmacology. 2007, 80 (4): 269-278. 10.1159/000106447. Yuan JH, Li YQ, Yang XY: Protective effects of epigallocatechin gallate on colon preneoplastic lesions induced by 2-amino-3-methylimidazo[4,5-f ] quinoline in mice. Mol Med. 2008, 14 (9-10): 590-598. 10.2119/2007-00050.Yuan. Kwak MK, Kensler TW: Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol. 2010, 244 (1): 66-76. 10.1016/j.taap.2009.08.028. Khor TO, Yu S, Kong AN: Dietary cancer chemopreventive agents - targeting inflammation and Nrf2 signaling pathway. Planta Med. 2008, 74 (13): 1540-1547. 10.1055/s-0028-1088303. Nair S, Li W, Kong AN: Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells. Acta Pharmacol Sin. 2007, 28 (4): 459-472. 10.1111/j.1745-7254.2007.00549.x. Katoh Y, Iida K, Kang MI, Kobayashi A, Mizukami M, Tong KI, McMahon M, Hayes JD, Itoh K, Yamamoto M: Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch Biochem Biophys. 2005, 433 (2): 342-350. 10.1016/j.abb.2004.10.012. Nguyen T, Nioi P, Pickett CB: The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009, 284 (20): 13291-13295. 10.1074/jbc.R900010200. Yuan X, Xu C, Pan Z, Keum YS, Kim JH, Shen G, Yu S, Oo KT, Ma J, Kong AN: Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol Carcinog. 2006, 45 (11): 841-850. 10.1002/mc.20234. Abraham NG, Kappas A: Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008, 60 (1): 79-127. 10.1124/pr.107.07104. Moi P, Chan K, Asunis I, Cao A, Kan YW: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA. 1994, 91 (21): 9926-9930. 10.1073/pnas.91.21.9926. Kwak MK, Wakabayashi N, Kensler TW: Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res. 2004, 555 (1-2): 133-148. Jeong WS, Jun M, Kong AN: Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal. 2006, 8 (1-2): 99-106. 10.1089/ars.2006.8.99. Lee LS, Stephenson KK, Fahey JW, Parsons TL, Lietman PS, Andrade AS, Lei X, Yun H, Soon GH, Shen P, Danlshefsky S, Flexner C: Induction of chemoprotective phase 2 enzymes by ginseng and its components. Planta Med. 2009, 75 (10): 1129-1133. 10.1055/s-0029-1185508. Halim M, Yee DJ, Sames D: Imaging induction of cytoprotective enzymes in intact human cells: coumberone, a metabolic reporter for human AKR1C enzymes reveals activation by panaxytriol, an active component of red ginseng. J Am Chem Soc. 2008, 130 (43): 14123-14128. 10.1021/ja801245y. Park SH, Jang JH, Chen CY, Na HK, Surh YJ: A formulated red ginseng extract rescues PC12 cells from PCB-induced oxidative cell death through Nrf2-mediated upregulation of heme oxygenase-1 and glutamate cysteine ligase. Toxicology. 2010, 278 (1): 131-139. Li J, Ichikawa T, Jin Y, Hofseth LJ, Nagarkatti P, Nagarkatti M, Windust A, Cui T: An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes. J Ethnopharmacol. 2010, 130 (2): 222-230. 10.1016/j.jep.2010.03.040. Kim SH, Park KS, Chang MJ, Sung JH: Effects of Panax ginseng extract on exercise-induced oxidative stress. J Sports Med Phys Fitness. 2005, 45 (2): 178-182. Lee LS, Wise SD, Chan C, Parsons TL, Flexner C, Lietman PS: Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius. J Clin Pharmacol. 2008, 48 (5): 599-609. 10.1177/0091270008314252. Wang Y, Ye X, Ma Z, Liang Q, Lu B, Tan H, Xiao C, Zhang B, Gao Y: Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells. Eur J Pharmacol. 2008, 601 (1-3): 73-78. 10.1016/j.ejphar.2008.10.057. Kim J, Cha YN, Surh YJ: A protective role of nuclear erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res. 2010, 690 (1-2): 12-23. Lin W, Wu RT, Wu T, Khor TO, Wang H, Kong AN: Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem Pharmacol. 2008, 76 (8): 967-973. 10.1016/j.bcp.2008.07.036. Liu H, Dinkova-Kostova AT, Talalay P: Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc Natl Acad Sci USA. 2008, 105 (41): 15926-15931. 10.1073/pnas.0808346105. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P: Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA. 2005, 102 (12): 4584-4589. 10.1073/pnas.0500815102. Ahn YH, Hwang Y, Liu H, Wang XJ, Zhang Y, Stephenson KK, Boronina TN, Cole RN, Dinkova-Kostova AT, Talalay P, Cole PA: Electrophilic tuning of the chemoprotective natural product sulforaphane. Proc Natl Acad Sci USA. 2010, 107 (21): 9590-9595. 10.1073/pnas.1004104107. Banning A, Florian S, Deubel S, Thalmann S, Muller-Schmehl K, Jacobasch G, Brigelius-Flohe R: GPx2 counteracts PGE2 production by dampening COX-2 and mPGES-1 expression in human colon cancer cells. Antioxid Redox Signal. 2008, 10 (9): 1491-1500. 10.1089/ars.2008.2047. Park YC, Lee CH, Kang HS, Kim KW, Chung HT, Kim HD: Ginsenoside-Rh1 and Rh2 inhibit the induction of nitric oxide synthesis in murine peritoneal macrophages. Biochem Mol Biol Int. 1996, 40 (4): 751-757. Surh YJ, Na HK, Lee JY, Keum YS: Molecular mechanisms underlying anti-tumor promoting activities of heat-processed Panax ginseng C.A. Meyer. J Korean Med Sci. 2001, 16 (Suppl): S38-41. Kim ND, Pokharel YR, Kang KW: Ginsenoside Rd enhances glutathione levels in H4IIE cells via NF-kappaB-dependent gamma-glutamylcysteine ligase induction. Pharmazie. 2007, 62 (12): 933-936. Oh GS, Pae HO, Choi BM, Seo EA, Kim DH, Shin MK, Kim JD, Kim JB, Chung HT: 20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-kappaB in RAW 264.7 macrophages stimulated with lipopolysaccharide. Cancer Lett. 2004, 205 (1): 23-29. 10.1016/j.canlet.2003.09.037. Darnell JE: Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002, 2 (10): 740-749. 10.1038/nrc906. Richmond A: Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002, 2 (9): 664-674. 10.1038/nri887. Nair S, Doh ST, Chan JY, Kong AN, Cai L: Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer. 2008, 99 (12): 2070-2082. 10.1038/sj.bjc.6604703. Wang H, Khor TO, Saw CL, Lin W, Wu T, Huang Y, Kong AN: Role of Nrf2 in suppressing LPS-induced inflammation in mouse peritoneal macrophages by polyunsaturated fatty acids docosahexaenoic acid and eicosapentaenoic acid. Mol Pharm. 2010, Kuang X, Scofield VL, Yan M, Stoica G, Liu N, Wong PK: Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. Brain Res. 2009, 1286: 174-184. 10.1016/j.brainres.2009.06.007. Cho HY, Gladwell W, Wang X, Chorley B, Bell D, Reddy SP, Kleeberger SR: Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice. Am J Respir Crit Care Med. 2010, 182 (2): 170-182. 10.1164/rccm.200907-1047OC. Saw CL, Huang Y, Kong AN: Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol. 2010, 79 (3): 421-430. 10.1016/j.bcp.2009.08.030. Cheung KL, Khor TO, Kong AN: Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation. Pharm Res. 2009, 26 (1): 224-231. 10.1007/s11095-008-9734-9.